Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2017-02-06 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab opdaterer resultatforventningerne til 2016
Earnings Release Classification · 95% confidence The document is a short company announcement (under 5,000 characters) providing an update to the company's 2016 financial guidance. It explicitly mentions that the full annual report will be published at a later date (February 22, 2017). Since it is an initial announcement of financial highlights rather than the full report itself, and it does not fit into specific categories like M&A or dividends, it is classified as an Earnings Release (ER). FY 2016
2017-02-06 English
Earnings Release 2016
Earnings Release Classification · 100% confidence The document is explicitly titled 'Company Announcement' and provides specific financial updates (net sales figures for DARZALEX in 2016, royalty income) related to a licensed drug. It is not a comprehensive annual report (10-K), a quarterly report (IR), or a formal earnings release (ER) which typically includes full P&L statements. It is a specific, periodic update on a key revenue driver, often released outside of standard quarterly reporting cycles to inform investors about commercial performance metrics. This type of targeted, non-standard financial disclosure fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure to the market about material information, but does not fit the more specific financial report codes (10-K, IR, ER). Given the content is a specific commercial update rather than a management discussion (MDA) or a presentation (IP), RNS is the most appropriate general regulatory disclosure category. FY 2016
2017-01-24 English
Earnings Release 2016
Earnings Release Classification · 100% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and is dated January 24, 2017. It provides specific financial updates regarding the net sales of the drug DARZALEX for the year 2016, including royalty information for Genmab. This structure—a brief announcement detailing key financial performance metrics for a specific period (2016 sales) and product—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on the *results* (sales figures) rather than announcing that a full report is attached (which would suggest RPA/RNS), and it is not a full quarterly/annual report (10-K or IR), the most appropriate classification is Earnings Release (ER). The document length (7732 chars) is substantial enough to contain key highlights, fitting the ER definition better than a short RPA. FY 2016
2017-01-24 Danish
Genmab offentliggør nettoomsætningen for DARZALEX® (daratumumab) i 2016
Earnings Release Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding specific financial figures (net sales of DARZALEX) for the 2016 fiscal year. It is not a full financial report (10-K or IR) but rather a targeted release of key financial highlights. According to the filing definitions, an initial announcement of quarterly or periodical financial results (key highlights only) is classified as an Earnings Release (ER). FY 2016
2017-01-24 English
Genmab offentliggør nettoomsætningen for DARZALEX® (daratumumab) i 2016
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Genmab regarding the 2016 net sales of their product DARZALEX. It provides specific financial figures (USD 572 million) and details regarding royalty agreements. While it contains financial data, it is a standalone announcement of specific product performance rather than a full quarterly or annual report. It fits the definition of a regulatory filing/announcement (RNS) as it is a formal company communication regarding financial performance metrics.
2017-01-24 English
M&A Activity 2017
M&A Activity Classification · 99% confidence The document is explicitly titled 'Company Announcement' and details a specific, non-recurring event: achieving a sales volume milestone in a collaboration (DARZALEX) resulting in a USD 25 million payment. This is not a comprehensive annual report (10-K), a quarterly report (IR), an earnings release (ER) focusing on overall period results, or a management discussion (MDA). It is a specific, material corporate event announcement. Since it is a specific announcement that doesn't fit the definitions for DIRS, DIV, CAP, MANG, or DLST, and it is not a presentation (IP) or a transcript (CT), the most appropriate general category for a material, non-standard corporate update that is not a full financial report is 'Regulatory Filings' (RNS), as it serves as a general regulatory disclosure to the market about a significant business development. Given the context of a biotech company announcing a milestone payment, it is a material event disclosure.
2017-01-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.